Who are Tolvaptan or Samsca's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Samsca, Physulime, Vaprisol In 5% Dextrose In Plastic Container, tolvaptan+torasemide, OPC-41061, OPC-41061 （Tolvaptan).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tolvaptan-or-samsca.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Tolvaptan or Samsca — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolvaptan or Samsca (Tolvaptan or Samsca) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin V2 receptor antagonist. Area: Cardiovascular.

phase 3 Vasopressin V2 receptor antagonist Vasopressin V2 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Tolvaptan or Samsca (Tolvaptan or Samsca) — Cardiovascular Clinical Sciences Inc. Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tolvaptan or Samsca TARGET	Tolvaptan or Samsca	Cardiovascular Clinical Sciences Inc	phase 3	Vasopressin V2 receptor antagonist	Vasopressin V2 receptor
Samsca	TOLVAPTAN	Otsuka	marketed	Vasopressin V2 Receptor Antagonist [EPC]	Vasopressin V2 receptor	2009-01-01
Physulime	MOZAVAPTAN	Otsuka Pharmaceutical Co., Ltd.	marketed	mozavaptan	Vasopressin V2 receptor	2006-01-01
Vaprisol In 5% Dextrose In Plastic Container	CONIVAPTAN	Cumberland	marketed	Vasopressin Receptor Antagonist	Vasopressin V2 receptor	2005-01-01
tolvaptan+torasemide	tolvaptan+torasemide	Shanghai Chest Hospital	marketed	Combination diuretic (vasopressin V2 receptor antagonist + loop diuretic)	Vasopressin V2 receptor (tolvaptan); Na-K-Cl cotransporter (torasemide)
OPC-41061	OPC-41061	Otsuka Pharmaceutical Co., Ltd.	phase 3	Vasopressin V2 receptor antagonist (vaptан)	Vasopressin V2 receptor
OPC-41061 （Tolvaptan)	OPC-41061 （Tolvaptan)	Otsuka Pharmaceutical Co., Ltd.	phase 3	Vasopressin V2 receptor antagonist	Vasopressin V2 receptor

Recent regulatory actions (last 90 days)

2026-04-21 — OPC-41061 · FDA · approved · US · Otsuka Pharmaceutical Co., Ltd.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin V2 receptor antagonist class)

BioLineRx, Ltd. · 1 drug in this class
Cardiovascular Clinical Sciences Inc · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tolvaptan or Samsca — Competitive Intelligence Brief. https://druglandscape.com/ci/tolvaptan-or-samsca. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing